While targeting therapies have significantly improved the survival ratio for hormone receptor positive and HER2 positive breast cancer subtypes, the clinical management of TNBC subtype is still challenging because of the lack of specific targets and the aggressive behaviour of the cancer cells [7, 8]. This evidence concerns the gene ERBB2 and breast cancer.